Antimicrobial peptides

Maxwell Biosciences Announces In Vivo and In Vitro Data on CLAROMER™  Platform’s Ability to Treat and Prevent SARS-CoV-2 and Other Respiratory Viruses at OPTIONS XI Conference

Retrieved on: 
Thursday, September 29, 2022
Biotechnology, Pharmaceutical, Health, Diamond, CO, Therapy, Twitter, Control, Virus, Severe acute respiratory syndrome coronavirus 2, Nature, LinkedIn, Company, List of life sciences, Antimicrobial peptides, Treatment, Maxwell, Glossary of patent law terms, Â, Public health, Option, Bacteria, International Society, Doctor of Philosophy, Fungus, Plasma protein binding, Tissue, Immune system, Drug discovery, Peptide, Toxicity, AMPS, Vaccine, Medication, Biotechnology, Pharmaceutical, Health

By targeting virus membranes and remaining well-tolerated in vivo, CLAROMERS may be able to retain these characteristics against current and future variants of concern.

Key Points: 
  • By targeting virus membranes and remaining well-tolerated in vivo, CLAROMERS may be able to retain these characteristics against current and future variants of concern.
  • Data was presented by Maxwell Biosciences Chief Scientific Officer and Co-Inventor, Kent Kirshenbaum, PhD, on Thursday, September 29, 2022, at the Options for Control of Influenza (OPTIONS XI) conference.
  • Data was presented under the abstract title, CLAROMERS: Synthetic Oligomer Mimics of Antimicrobial Peptides for Treatment and Prevention of SARS-CoV-2 and Other Respiratory Viruses.
  • To learn more about Maxwell Biosciences, visit MaxwellBiosciences.com , or follow us on Twitter and LinkedIn .

Maxwell Biosciences to Present Data on CLAROMERTM Platform’s Treatment and Prevention of SARS-CoV-2 and Other Respiratory Viruses at OPTIONS XI Conference

Retrieved on: 
Thursday, September 22, 2022
Infectious Diseases, General Health, Health, Clinical Trials, CO, Therapy, COVID-19, Twitter, XI, Virus, Control, Severe acute respiratory syndrome coronavirus 2, Nature, LinkedIn, Company, List of life sciences, Antimicrobial peptides, Treatment, Maxwell, Glossary of patent law terms, Option, Bacteria, International Society, Doctor of Philosophy, Fungus, Tissue, Research, Immune system, Toxicity, Vaccine

Kent Kirshenbaum, PhD, Maxwell Biosciences Chief Scientific Officer and Co-Inventor, will present the abstract, CLAROMERS: Synthetic Oligomer Mimics of Antimicrobial Peptides for Treatment and Prevention of SARS-CoV-2 and Other Respiratory Viruses, on Thursday, September 29, 2022, at 2:06 BST.

Key Points: 
  • Kent Kirshenbaum, PhD, Maxwell Biosciences Chief Scientific Officer and Co-Inventor, will present the abstract, CLAROMERS: Synthetic Oligomer Mimics of Antimicrobial Peptides for Treatment and Prevention of SARS-CoV-2 and Other Respiratory Viruses, on Thursday, September 29, 2022, at 2:06 BST.
  • What makes Maxwells CLAROMER platform unique from standard antivirals is its ability to combat a broad spectrum of viruses, bacteria and fungi, said Maxwell Biosciences CEO and Co-Founder Joshua McClure.
  • We look forward to presenting results from our most recent research on ways to potentially innovate the treatment of COVID-19 and other infectious pathogens."
  • Founded in 2016, Maxwell Biosciences is a preclinical drug platform company which develops biomimetic therapeutics synthetic compounds that mimic and improve upon biomolecules.

2021 Market Report on Hepcidin Drugs in Development - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 3, 2021
Health, Pharmaceutical, Medical specialties, Branches of biology, Iron metabolism, Blood proteins, Hepatology, Peptide hormones, Hepcidin, Immune system, Hamp, Antimicrobial peptides, Liver, HEPC

The "Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Drugs in Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Drugs in Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to this report the pipeline Target constitutes close to 5 molecules.
  • Hepcidin is a protein encoded by the HAMP gene.
  • It also reviews key players involved in Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics development with respective active and dormant or discontinued projects.

New Research Findings Published in Pharmaceuticals Identify Novel Peptoids with Potent Antiviral Activity Against HSV-1 and SARS-CoV-2

Retrieved on: 
Monday, April 5, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Other Health, Medical specialties, Medicine, Clinical medicine, Sarbecovirus, Antiviral drugs, Antimicrobial peptides, Immune system, Immunology, Herpes simplex virus, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Antimicrobial

Titled Potent Antiviral Activity against HSV-1 and SARS-CoV-2 by Antimicrobial Peptoids , the research findings demonstrate that several peptoids exhibit potent in vitro antiviral activity against both HSV-1 and SARS-CoV-2.

Key Points: 
  • Titled Potent Antiviral Activity against HSV-1 and SARS-CoV-2 by Antimicrobial Peptoids , the research findings demonstrate that several peptoids exhibit potent in vitro antiviral activity against both HSV-1 and SARS-CoV-2.
  • Their antiviral activity was studied and tested at the University of Louisville with financial support from Maxwell Biosciences .
  • To determine whether the peptoids exhibited activity against enveloped viruses, the researchers tested the in vitro inhibitory activity of peptoids MXB-4 and MXB-9 against SARS-CoV-2.
  • Since antimicrobial peptides such as LL-37 exhibit potent activity against HSV-1 [ 36 ], their potential as antiviral preventive or therapeutic agents is significant.

PLG0206: An Engineered, Cationic Antibiotic Peptide - Global Sales, Emerging Insight and Market Forecast, 2017-2020 & 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 18, 2021
Health, Other Health, Medical specialties, Medicine, Clinical medicine, Peripheral membrane proteins, Antimicrobial peptides, Immune system, Immunology, Antibiotic, Peptide

PLG0206 is an engineered, cationic antibiotic peptide, and is a next generation agent based on the principles found in naturally occurring antimicrobial peptides (AMPs).

Key Points: 
  • PLG0206 is an engineered, cationic antibiotic peptide, and is a next generation agent based on the principles found in naturally occurring antimicrobial peptides (AMPs).
  • "PLG0206 - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Prosthetic Joint Infection in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
  • Other emerging products for Prosthetic Joint Infection are giving market competition to PLG0206 and launch of late-stage emerging therapies in the near future will significantly impact the market.

Global Peptide Therapeutics Market Therapy Size Companies Trends Clinical Pipeline Insight 2026

Retrieved on: 
Wednesday, November 11, 2020
Peptides, Peptide, Branches of biology, C-peptide, Biology, Life sciences, Antimicrobial peptides

"Global Peptide Therapeutics Market & Clinical Pipeline Insight 2026" report highlights:

Key Points: 
  • "Global Peptide Therapeutics Market & Clinical Pipeline Insight 2026" report highlights:
    Global Peptide Therapeutics Market Opportunity: US$ 65 Billion
    Insight Peptide Drugs in Clinical Trials: 807 Peptides Drugs
    Peptide Clinical Pipeline Is Dominated by Cyclic Peptides: 46 Peptides
    Peptides Clinical Trials Insight by Phase, Indication & Company
    In a broad sense, peptide cancer drugs are involved in narrowing down the growing cancer mortality rate by performing such tasks which have been difficult to achieve with the other traditional cancer therapeutics.
  • There are several different trends and opportunities that are related with the market of peptide cancer drugs.
  • In the overall cancer therapeutics market, several different pharma companies have adopted this therapy and are running their research and development sector in bringing the most desirable peptide drug products in the market.
  • It is estimated that the market will soon explore all the undefined parameters and will indulge itself in the list of cutting-edge technology in the therapeutics market.

Global Peptide Therapeutics Market Therapy Size Companies Trends Clinical Pipeline Insight 2026

Retrieved on: 
Wednesday, November 11, 2020
Peptides, Branches of biology, Peptide, Biochemistry, Biology, Antimicrobial peptides

Cancer Peptides To Account for More than 25% of Global Peptide Drugs Sales, Says Kuick Research

Key Points: 
  • Cancer Peptides To Account for More than 25% of Global Peptide Drugs Sales, Says Kuick Research
    "Global Peptide Therapeutics Market & Clinical Pipeline Insight 2026" report highlights:
    Global Peptide Therapeutics Market Opportunity: US$ 65 Billion
    Insight Peptide Drugs in Clinical Trials: 807 Peptides Drugs
    Peptide Clinical Pipeline Is Dominated by Cyclic Peptides: 46 Peptides
    Peptides Clinical Trials Insight by Phase, Indication & Company
    In a broad sense, peptide cancer drugs are involved in narrowing down the growing cancer mortality rate by performing such tasks which have been difficult to achieve with the other traditional cancer therapeutics.
  • There are several different trends and opportunities that are related with the market of peptide cancer drugs.
  • In the overall cancer therapeutics market, several different pharma companies have adopted this therapy and are running their research and development sector in bringing the most desirable peptide drug products in the market.
  • It is estimated that the market will soon explore all the undefined parameters and will indulge itself in the list of cutting-edge technology in the therapeutics market.

The Global Animal Antibacterial Peptide Market is expected to grow from USD 1,896.66 Million in 2019 to USD 4,591.36 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 15.87%

Retrieved on: 
Monday, July 27, 2020
Medical specialties, Medicine, Clinical medicine, Antimicrobial peptides, Immune system, Immunology, Antibiotic, Bacteria

On the basis of Product Origin, the Animal Antibacterial Peptide Market is studied across Cattle, Goat, Horse, Pig, Poultry, and Sheep.

Key Points: 
  • On the basis of Product Origin, the Animal Antibacterial Peptide Market is studied across Cattle, Goat, Horse, Pig, Poultry, and Sheep.
  • On the basis of Geography, the Animal Antibacterial Peptide Market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa.
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Animal Antibacterial Peptide Market during the forecast period?
  • What are the modes and strategic moves considered suitable for entering the Global Animal Antibacterial Peptide Market?

Arrevus Receives Dual Awards from NIH and Department of Defense for Development of ARV-1502

Retrieved on: 
Friday, May 29, 2020
Research, Other Defense, Surgery, Infectious diseases, Other Health, Biotechnology, Pharmaceutical, Health, Science, Defense, Medical specialties, Medicine, Branches of biology, Medical emergencies, Injuries, Infectious diseases, Antimicrobial peptides, Immune system, Wound, Sepsis, Surgery, ARV

Gram-negative bacterial-associated wounds result in > 40% increase in mean number of ICU days and 75% greater number of surgical procedures.

Key Points: 
  • Gram-negative bacterial-associated wounds result in > 40% increase in mean number of ICU days and 75% greater number of surgical procedures.
  • The clinical utility of engineered host defense peptides, such as ARV-1502, is a fertile area for development for both the commercial and military markets.
  • Arrevus is pioneering a novel approach to infections, sepsis and wound healing through the development of Designer Proline-rich Chaperone protein inhibitors (DPCs), with the lead compound being ARV-1502.
  • Arrevus is headquartered in Raleigh, N.C. For more information about Arrevus Inc., visit www.arrevus.com or email [email protected] .

Innovation Pharmaceuticals’ Brilacidin Reduces Viral Titer of SARS-CoV-2 (COVID-19) by 75 percent After Only 1 Hour of Preincubation in In Vitro Study at BSL-3 Facility; Demonstrates Potent and Rapid Virucidal Activity

Retrieved on: 
Tuesday, May 19, 2020
Viruses, Medical specialties, Medicine, Biocides, Animal virology, Zoonoses, Coronavirus, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, Antiviral drug, Antimicrobial peptides, Antimicrobial

A majority of antiviral agents targeting SARS-CoV-2 attempt to inhibit viral replication rather than completely eliminating the virus (virustatic versus virucidal).

Key Points: 
  • A majority of antiviral agents targeting SARS-CoV-2 attempt to inhibit viral replication rather than completely eliminating the virus (virustatic versus virucidal).
  • The review article linked below more broadly supports the therapeutic and prophylactic potential of Host Defense Proteins/Antimicrobial Peptides and their mimetics, like Brilacidin, against coronaviruses.
  • An earlier 16-hour post-infection experiment, in VERO cells, showed Brilacidin exhibited a dose-dependent reduction in SARS-CoV-2 infectious viral titers.
  • A more complete description of these risk factors is included in the Companys filings with the Securities and Exchange Commission.